Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 2a, open-label, non-randomized, 2-part multicenter, combination Study of NMS-01940153E and Atezolizumab with or without a prior priming with low dose decitabine for the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma (HCC) Previously Treated with Immune Checkpoint Inhibitors

X
Trial Profile

A phase 2a, open-label, non-randomized, 2-part multicenter, combination Study of NMS-01940153E and Atezolizumab with or without a prior priming with low dose decitabine for the Treatment of Adult Patients with Unresectable Hepatocellular Carcinoma (HCC) Previously Treated with Immune Checkpoint Inhibitors

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs S 81694 (Primary) ; Atezolizumab; Decitabine
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2025 New trial record
    • 07 Jan 2025 According to a Nerviano Medical Sciences media release, company announces launch of new clinical trial NMS-153 in Combination with Atezolizumab and clinical trial agreement with Roche and Roche is the collaborator of this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top